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Abstract: Amyotrophic lateral sclerosis is a rare and fatal neurodegenerative disease characterised by
progressive deterioration of upper and lower motor neurons that eventually culminates in severe
muscle atrophy, respiratory failure and death. There is a concerning lack of understanding regarding
the mechanisms that lead to the onset of ALS and as a result there are no reliable biomarkers
that aid in the early detection of the disease nor is there an effective treatment. This review first
considers the clinical phenotypes associated with ALS, and discusses the broad categorisation of
ALS and ALS-mimic diseases into upper and lower motor neuron diseases, before focusing on the
genetic aetiology of ALS and considering the potential relationship of mutations of different genes to
variations in phenotype. For this purpose, a systematic review is conducted collating data from 107
original published clinical studies on monogenic forms of the disease, surveying the age and site of
onset, disease duration and motor neuron involvement. The collected data highlight the complexity
of the disease’s genotype–phenotype relationship, and thus the need for a nuanced approach to the
development of clinical assays and therapeutics.
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1. Introduction
Amyotrophic lateral sclerosis, or ALS, is characterised by a progressive and fatal degeneration of
upper and/or lower motor neurons (UMN and LMN, respectively) resulting in muscle weakness and
wasting. Classical ALS is the most common form of motor neuron disease (MND) [1] and is defined by
the selective deterioration of both UMN and LMN [2]. The global incidence of ALS varies between 1
and 2.6 cases per 100,000 people per year [3], with the average age of onset ranging from 54 to 67 years
old [4]. The prevalence of ALS increases with age, reaching 1/5000 among people aged 70–79 years
old [5]. Consequently, as the population ages, it is expected that the world’s total number of cases
will reach more than 375,000 by 2040 [6]. Owing to the lack of a reliable diagnostic test, absence of
validated biomarkers, and phenotypes that are easily confounded with other MNDs, including primary
lateral sclerosis (PLS) and progressive muscular atrophy (PMA), there is a delay of approximately
11–12 months in reaching a definite diagnosis [7]. Currently, diagnosis is based on a set of clinical
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criteria (El Escorial [8] and revisions [9], and Awaji-Shima criteria [10]) that can be used to stratify
patients according to the area of initial onset and the progression of symptoms.
ALS phenotypes vary between patients who can present with different sites of onset and symptom
severity (Figure 1). Concomitant impairments in cognitive ability are sometimes associated with
the ALS phenotype. A recent finding from Chiò et al. suggested that 20.5% of ALS patients had
frontotemporal dementia (FTD), and a further 31.3% had a behavioural, cognitive or non-executive
impairment [11].
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In the past 30 years, there have been a large number of studies investigating the genetic 
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note that mutations in these genes explain only ~20% of total ALS cases [14] whilst the majority of 
cases remain unexplained and present no family history. ALS is therefore considered to be a mainly 
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To understand the molecular mechanisms underlying ALS, it is useful to study genotype–
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certain gene mutations, and several informatics resources exist to collect genotype–phenotype data 
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In the past 30 years, there have been a large number of studies investigating the genetic
underpinnings of ALS. To date, over 30 genes have been related to the disease; yet it is important to
note that mutations in these genes explain only ~20% of total ALS cases [14] whilst the majority of
cases remain unexplained and present no family history. ALS is therefore considered to be a mainly
sporadic disease (sALS), with ~80% of cases having no known genetic basis [3], although twin studies
have estimated heritability at 40–45% [15] or 61 [16]. Kno n gene utations explain some 70%
of familial cases (fALS) [17,18], and they have also been identified in 10% of sporadic cases [18]. In
European cohorts, the hexanucleotide repeat expansion in the C9orf72 gene is the most common genetic
cause of fALS (33.7%) and sALS (5.1%), followed by SOD1 (14.8% in fALS and 1.2% in sALS cases),
TARDBP/TDP-43 (4.2% in fALS and 0.8% in sALS), and FUS (2.8% in fALS and 0.3% in sALS) [19].
To understand the molecular mechanisms underlying ALS, it is useful to study
genotype–phenotype relationships, to determine whether certain gene mutations are associated
with specific clinical features or outcomes. Genotype–phenotype relationships have previously
been examined for certain gene mutations, and several informatics resources exist to collect
genotype–phenotype data [20–24], but a systematic understanding across different gene mutations has
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not been established. As a step towards this, the present review gathers together the clinical summary
statistics from previously studied cohorts across 22 of the more commonly associated genes. Each of
the genes are considered in the order in which they were discovered and, where available, a summary
of the reported phenotypes associated with each gene is later provided.
2. Pathological Definition of ALS: Clinical Features and Phenotype Variability
2.1. Age of Onset Variation
ALS occurs primarily in patients in their sixth decade, though peak onset is later in sporadic cases
(58–63 years) than in familial cases (47–52 years) [25] (Table 1 and Figure 1). Four periods of onset
can be defined: juvenile (<25 years old); young (25–45 years); mid–late adulthood (45–70 years); and
elderly (>70 years). Juvenile ALS is extremely rare (<1/1,000,000 cases) [26], and is usually associated
with slower symptom progression, hence a longer survival time and better prognosis [27]. Some
mutations are now described to be associated with juvenile ALS, such as specific mutations of FUS,
ALS2 and SETX genes [26]. UMN rather than LMN dysfunction is predominant among juvenile ALS
cases. Young-onset ALS also shows mainly UMN dysfunction, which is predominant in 60% of those
patients [26]. Bulbar-onset ALS is rare in young patients and represents ~15% of cases [27]. In addition,
young-onset ALS affects a relatively high proportion of males, with a male:female ratio of 3:1 [26]. These
young-onset cases are also associated with a better prognosis than older ALS patients. Elderly-onset
patients are more likely to present with bulbar symptoms and are represented by a greater proportion
of female patients (M:F ratio 1–1.6) [12,26]. Symptom onset after 80 years is associated with a more
aggressive phenotype and poor prognosis, with mean survival times of less than 20 months [12].
Table 1. ALS age of onset variability and their clinical features. Summary of clinical features for ALS
in different age periods from Chio et al. [28], Forbes et al. [12], Swinnen et al. [27], Turner at al [26],
Sabetelli et al. [29], and Kiernan et al. [25]. In addition to the classical ALS phenotype with age of
onset ranging from 45 to 70 years old (mean age ~ 61 years old), three additional age of onset periods
(columns) have been observed. Male to female ratios, genetic characteristics, site of onset, estimated
survival time, and clinical features are shown where applicable. sALS: sporadic ALS. fALS: familial
ALS. MN: motor neurons. UMN: upper motor neurons. LMN: lower motor neurons. -: no data.
Juvenile Young Mid–LateAdulthood Elderly
Age of onset ≤25 years old 25 to 45 years old 45 to 70 years old >70 years old
M:F ratio _ 3–3.6:1 1.3–1.56:1 1:1.25
Genetics
Mostly familial
cases (FUS, SETX,
ALS2 mutations)
Mostly familial ~90% sALS~10% fALS _
Site of onset:
Limb onset _ _ ~70% ~40%
Bulbar onset _ ~16% ~25% ~50% (M:F = 1:1.6)
Respiratory/cognitive
onset _ _ ~5% _
Survival (from
symptoms onset) Generally longer survival > 10 years
Variable:
50%: <30 months
5–10%: 5–10 years
~20 months
MN involvement:
UMN+LMN _ ~40% ~80% ~72%
UMN-predominant Predominant ~60% ~17% _
LMN-predominant _ _ _ ~19%
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2.2. Site of Onset Variability
The majority of ALS cases (~70%) have spinal onset, usually presenting with focal limb
weakness [30] such as foot drop or a weak hand [7]. The disease then tends to spread in a contiguous
manner, initiating at distinct focal regions of the body and then propagating from the primarily affected
area to adjuvant secondary sites of the body [31].
In 25% of ALS cases, symptoms develop initially in the bulbar-innervated muscles [30,32].
Bulbar-onset ALS is more common in women [7], especially after 70 years (M:F ratio 1:1.6 [12]).
Dysarthria almost always predates dysphagia and cognitive impairment is often present [32].
Approximately 3% to 5% of patients [33] present with respiratory or cognitive onset [25]. Thoracic
spinal-onset ALS can present as truncal weakness or respiratory impairment and is associated with
poor prognosis, with a mean survival time of just 1.4 years [27,34].
Cognitive-onset ALS patients usually present symptoms characteristic of frontotemporal dementia
(FTD), such as changes in behaviour, personality and cognition which are all suggestive of frontal
impairments [35].
In summary, initial site of symptom onset varies among ALS patients from classic limb-onset to
rare cognitive-onset phenotypes, and a poor prognosis is often associated with bulbar and respiratory
onset [25].
2.3. Motor Neuron Involvement in ALS Variants
ALS patients can present with either a LMN or UMN predominant phenotype (Figure 2). Signs of
pure LMN dysfunction are considered as progressive muscular atrophy (PMA), whereas predominant
UMN signs are associated with primary lateral sclerosis (PLS) [30]. PMA and PLS are both rare diseases
and represent 5% of MND patients [27].
2.3.1. UMN-Dominant ALS Variants
Patients can present predominant UMN dysfunction as in primary lateral sclerosis (PLS) or
pseudobulbar palsy. The UMN predominant phenotype can then progress to ALS, which is observed
in 40% of PLS cases [36]. Patients diagnosed with PLS for not meeting the diagnostic criteria for
ALS can still slowly develop signs of LMN dysfunction and therefore present both UMN and LMN
signs [27]. However, LMN involvement and limb atrophy in PLS is exceptionally rare [37] and the
prognosis for PLS patients is better than that for patients diagnosed with ALS as symptom progression
is relatively slow.
2.3.2. LMN-Dominant ALS Variants
On the contrary, some patients can develop a LMN-dominant phenotype which can be defined
as progressive muscular atrophy (PMA), and flail-arm or flail-leg syndrome variants. PMA patients
are similar to classic ALS patients without obvious signs of UMN dysfunction. However 50% to
60% of PMA patients develop degeneration of upper motor neurons during the progression of the
disease [38], and post-mortem histopathology has demonstrated that some PMA patients show UMN
involvement which could not be detected upon clinical examination [39,40]. In patients with flail-arm
or flail-leg syndromes, a LMN pattern of weakness and atrophy is observed in the upper limbs or
lower limbs, respectively. Similar to PMA, flail-arm and flail-leg syndrome have been described as
a LMN variant but can show UMN involvement in the later stages of disease [41]. Involvement of
secondary sites should not occur within 12 months of initial onset [42] and prognosis for flail-arm and
flail-leg syndrome is better than that seen in ALS, with median survival times of 5 to 6 years [41,43].
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them, but it should be noted that the number of patients and studies for which these clinical parameters
are reported is relatively small (Table S2). ALS and FTD are sometimes described as part of one
continuum, with pure ALS patients (without any non-motor involvement) and pure FTD cases (for
whom no motor dysfunction has been described) representing opposite ends of the spectrum.
ALS patients having FTD usually meet the criteria for behavioural variant FTD characterised
by defects in cognitive functions, personality traits and behavioural collapse. Among ALS cases
experiencing non-motor dysfunction, language (particularly deficits in verbal fluency) and cognition
are the most affected categories [49], and apathy is the most frequently encountered personality
impairment [47].
2.4.1. Dementia in ALS Patients—ALS-FTD Variants
ALS-FTD diagnosis is made upon the presence of an ALS phenotype associated with behavioural or
cognitive defects that fulfil FTD diagnostic criteria: (1) progressive impairment of behavioural/cognitive
functions and observation of at least three behavioural symptoms defined by Rascvosky et al. [50];
or (2) loss of insight and/or presence of psychotic features associated with at least two Rascvosky et
al. [50] symptoms; or (3) language impairment combined with semantic dementia (defined in [48]).
2.4.2. Cognitive Changes in Non-Demented ALS Patients—ALSci and ALSbi Variants
Non-demented ALS patients presenting with behavioural impairment are classified as
ALSbi-variant, while ALS patients experiencing cognitive impairment including language defects are
considered to be ALSci variant [47]. Based on the revised diagnostic criteria from Strong et al. [51], ALS
patients can be diagnosed as ALSci variant if either executive impairment (social cognition), or language
dysfunction, or a combination of the two features are evident during diagnosis. Diagnostic criteria for
ALSbi variant require apathy with or without other behavioural symptoms, or two or more behavioural
changes, such as disinhibition, loss of sympathy/empathy, perseverative/stereotypic/compulsive
behaviour, hyper orality/dietary change, loss of insight and psychotic symptoms.
3. Genetics of ALS
Superoxide dismutase 1 (SOD1) was the first gene demonstrated to be associated with ALS in
1993 [52]. SOD1 is ubiquitously expressed in human cells and serves to protect them from harmful
reactive oxygen species (ROS). Mutated forms of SOD1 are believed to result in a toxic gain of function,
provoking the presence of misfolded protein aggregates, increased endoplasmic reticulum (ER) stress,
and oxidative stress and ultimately accelerating motor neuron degeneration [17].
In 2001, mutations in ALSIN2 (ALS2) were shown to be implicated in juvenile forms of ALS [53–55]
and PLS [56]. The ALS2 protein has been found to act as a guanine nucleotide exchange factor for
the GTPase, Rab5, which is in involved in endosome trafficking [57]. Mutations in ALS2 have been
shown to inhibit activation of Rab5 and its translocation to mitochondria, leaving ALS2 mutated motor
neurons more susceptible to oxidative stress [58]. However, in murine studies, genetic ablation of
ALS2 has failed to recapitulate the pathological features seen in ALS [59,60] although primary motor
neurons from these mice did show greater sensitivity to oxidative stress and aberrant morphology,
suggesting that ALS2 mutations may indeed play a role in motor neuron susceptibility in ALS.
Genetic mutations were next reported in 2004 for the senataxin (SETX), angiogenin (ANG), and
vesicle-associated membrane protein-associated protein B (VAPB) genes. SETX plays a role in numerous
cellular functions including RNA metabolism and has been shown to regulate RNA polymerase
II transcription termination [61] and its yeast homolog, SEN1, has been linked with processing of
non-coding RNA [62]. SETX mutations are strongly associated with juvenile-onset ALS [63] and
associations have been confirmed in American, Italian and Dutch cohorts [63–65]. ANG is highly
expressed in the human central nervous system [66] and has been reported to show neuroprotective
properties [67]. Indeed, expression of ALS-associated ANG variants has been shown to cause motor
neuron death in cell culture models [67]. ANG has also been reported to play a role in the transcription
J. Pers. Med. 2020, 10, 58 7 of 28
of ribosomal RNA [68] and many ALS-associated variants are believed to elicit a loss of function in
ANG, thus eliminating any neuroprotective functionality [69]. VAPB is a protein closely associated
with the endoplasmic reticulum and is thought to be involved in the induction of the unfolded protein
response (UPR) [70], as well as cellular processes including lipid transport [71], protein secretion [72],
and calcium homeostasis [73]. The P56S mutation in VAPB has been implicated in an early-onset and
slow-progressing form of fALS [74] and follow-up studies have highlighted how this mutation can
result in nuclear envelope defects [75], and provoke VAPB ER aggregates [72]. However, murine
models expressing the P56S mutation show widespread VAPB aggregates but demonstrate no motor
neuron pathology or ALS phenotypes [76].
The next genetic mutation associated with ALS did not arrive until 2008, when mutations in
TAR DNA-binding protein (TARDBP), encoding TDP-43, were reported in patients [77]. TDP-43 is a
RNA/DNA-binding protein that plays important roles in several RNA metabolism processes [78].
Ubiquitinated TDP-43 was first shown to be present in CNS inclusions of ALS patients in 2006 [79] and
subsequent studies have confirmed TDP-43 as the major protein component of pathological inclusions
present in approximately 90% of ALS patients [80]. However, TDP-43 pathology is not unique to ALS
and has been reported in numerous neurodegenerative conditions including FTD [79], Parkinson’s
disease [81], Huntington’s disease [82], Alzheimer’s disease [83], and dementia with Lewy bodies [84].
Then, in 2009, multiple mutations in the nuclear RNA-binding protein, Fused in Sarcoma (FUS)
and FIG4 phosphoinositide 5-phosphatase (FIG4), were associated with ALS [85,86]. FUS is another
RNA/DNA-binding protein involved in mechanisms of RNA splicing and DNA repair [87] and is
implicated in both ALS and FTD [88]. Mutations in FUS, particularly those near the nuclear localisation
signal (NLS) domain, cause cytoplasmic protein mislocalisation and are associated with a severe
phenotype in murine models [89]. FIG4 is involved in vesicle trafficking due to its role in the regulation
of the membrane bound phosphoinositide, PI(3,5)P2 [90]. Mutations in FIG4 were initially shown
to cause neurodegeneration in Charcot–Marie–Tooth (CMT) neuropathy [91]. However, others have
questioned the role of FIG4 in ALS pathology after failing to find pathogenic mutations in their
Taiwanese [92] and Italian [93] cohorts.
In 2010, mutations in Optineurin (OPTN), Spatacsin paraplegia 11 (SPG11), Valosin-containing
protein (VCP), and Ataxin-2 (ATXN2) were all implicated in ALS. Three different OPTN mutations were
identified in ALS patients [94] and researchers were able to demonstrate the increased immunoreactivity
of OPTN in both TDP-43 and SOD1 inclusions found in the spinal cord of sALS patients, suggesting a
role for OPTN in general ALS pathogenesis.
The link between SPG11 and ALS was established when mutations were found to be associated
with autosomal recessive juvenile ALS [95]. Mutations to SPG11 are the most common cause of
autosomal recessive hereditary spastic paraplegia [96] and loss of function mutations have been shown
to elicit lysosomal dysfunction and UMN + LMN degeneration in mice [97]. ATXN2 encoding the
ataxin-2 polyglutamine (polyQ) protein was associated with ALS when researchers identified the
presence of intermediate length polyQ expansions (27-33 Qs) in 4.7% of their North-American ALS
cohort [98]. Ataxin-2 protein has been shown to regulate mRNA stability and translation [99,100] and
upregulation of the fly homolog of Ataxin-2 was found to enhance neurodegeneration in Drosophila
via its interaction with wild-type and mutated forms of TDP-43 [98]. Involvement of Ataxin-2 in ALS
pathogenesis has since been confirmed in European and Chinese patient cohorts [101,102]. VCP is
an ATP-driven chaperone protein that plays a role in ubiquitin-regulated protein degradation [103],
autophagy [104], and mRNA processing [105,106]. VCP mutations were shown to be present in 1–2%
of familial ALS patients in an Italian cohort [107] and mice expressing ALS-associated VCP mutations
have been shown to develop a slow-progressing ALS phenotype [108].
In 2011, mutations in ubiquilin-2 (UBQLN2), sequestosome-1 (SQSTM1), and chromosome 9 open
reading frame 72 (C9orf72) were discovered. Ubiquilin-positive inclusions have been implicated in
both sALS and fALS [109], whilst mutations in SQSTM1 have been observed in rare ALS and FTD
cases [110] and can be shown to lead to p62 protein inclusions in motor neurons of both patient
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groups [111]. The G4C2 hexanucleotide repeat expansion mutation (HREM) within C9orf72 [112,113]
is perhaps the most significant genetic mutation associated with ALS thus far, and is estimated to be
present in 34% of familial cases, and 5% of sporadic cases in Europe [19,114]. In healthy subjects, the
G4C2 repeat length ranges from 2 to 23 units [112], whilst intermediate expansions ranging from 24 to
30 [115] and large expansions ranging from 30 to many hundreds of units have been observed in ALS
patients [112,116]. Although rare, C9orf72 expansions have been implicated in other neurodegenerative
and psychiatric diseases including PD [117] and Schizophrenia [118], suggesting a wider role for
C9orf72 in neuropathology and perhaps offering some insight towards the heterogeneous phenotype
seen in C9orf72 ALS.
In 2012, Profilin 1 (PFN1) was implicated in familial and sporadic cases of ALS [119]. Mutant PFN1
has been shown to cause motor neuron degeneration through the formation of insoluble aggregates
and disrupted cytoskeleton dynamics in mice [120] and co-aggregation of PFN1 and TDP-43 has been
reported in cell lines expressing mutant PFN1 [119].
Then, in 2013, heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) was reported to be involved in
ALS after researchers identified three hnRNPA1 variants—two of which were associated with familial
ALS and the other of which was associated with a sporadic case [121]. hnRNPA1 is known to colocalise
with TDP-43 [121] and post-mortem studies have shown that motor neurons of ALS patients display
marked reductions in hnRNPA1 alongside concomitant TDP-43 inclusions [122].
In 2014, mutations in Tubulin alpha-4A (TUBA4A) and Matrin-3 (MATR3) were implicated in ALS.
Mutations in TUBA4A were first identified in a European and American cohort [123] and then validated
in Belgian and Chinese cohorts in 2017 and 2018 [124,125]. TUBA4A mutations have been shown to
cause cytoskeletal defects in primary motor neurons [123] and are recognised as a rare cause of ALS
and FTD [125].
MATR3 was first associated with ALS after exome sequencing identified mutations in Italian, UK
and US kindreds, alongside increased levels of MATR3 protein in spinal cord sections of ALS patients
relative to controls [126]. MATR3 has been found to interact with TDP-43 and both proteins were shown
to co-aggregate in skeletal muscle tissue of ALS patients [126]. MATR3 is known to play various roles
in RNA metabolism and alternative splicing [127,128] and recent evidence suggests ALS-associated
MATR3 mutations play a role in defective nuclear export of FUS and TDP-43 mRNA [129]
In 2015, NIMA-related kinase 1 (NEK1) was recognised as an ALS-risk gene [130] and was shown to
interact with two other ALS genes, ALS2 and VAPB—both of which are involved in endosomal trafficking.
Subsequent studies provided further evidence for the pathogenic role of NEK1 in ALS [131,132] and
pathway analyses have shown NEK1 to interact with C21orf72—both of which are involved in DNA
repair mechanisms [133]. Mutations in Tank-binding kinase 1 (TBK1) were also associated with ALS in
2015 after exome sequencing identified eight loss of function mutations in 13 fALS pedigrees [134].
Cyclin F (CCNF) was implicated in ALS in 2016 with variants identified in both familial and
sporadic cases [135]. In the same study, researchers were able to demonstrate how mutant CCNF
led to aberrant ubiquitination and aggregation of proteins including TDP-43. More recently, CCNF
was shown to be a binding partner of another ALS protein, VCP. Binding of mutated CCNF to VCP
increased VCP ATPase activity, which in turn led to increased TDP-43 aggregation in U20S cells [136].
Then, in 2018, the most recent genetic mutations implicated in ALS were discovered when research
demonstrated the pathological involvement of Kinesin family member 5A (KIF5A) [137]. KIF5A is a protein
expressed specifically in neurons and is involved in regulating neuronal microtubule dynamics [138,139].
KIF5A is also associated with spastic paraplegia and Charcot–Marie–Tooth neuropathy [140] and
mutations have been reported in ALS patients in Chinese [141], European [142,143], and US cohorts [137].
4. Correlation of Genotype/Phenotype: Methods, Results and Discussion
To evaluate whether there is a correlation between associated genes and phenotype in ALS, a
systematic search of original papers was performed using key words summarised in Table S1, while
adhering to PRISMA guidelines (see checklist in Supplementary Materials).
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4.1. Protocol
A systematic search was performed in PubMed using the key words: ALS, genotype phenotype,
patient, and onset. To make sure that clinical data would also be obtained for rare genes involved in
ALS and listed in Vijayakumar et al. [14], the following search terms were added: ALS, phenotype,
patient and the gene name such as TBK1, VCP, SQSTM1, CCNF, NEK1, OPTN, FIG4, PFN1, ATXN2,
VAPB, ANG, ALS2, SPG11, UBQLN2, KIF5A, and MATR3. There were no language, type of study, or
publication date restrictions.
4.2. Eligibility Criteria
The search combining the different key words resulted in 355 articles. Reviews and duplicated
papers were excluded. To avoid redundancy, papers re-using previously published clinical data were
excluded. All studies used in the systematic review were peer-reviewed, written in English, and
published original clinical data related to patients affected by monogenic forms of ALS. At least one of
the following parameters had to be described in the paper: age of onset, site of onset, motor neuron
population being affected (UMN, LMN, UMN+LMN), disease duration, number of patients with FTD,
and number of patients with cognitive impairment. A total of 107 papers were then eligible for the
analysis (see PRISMA flow chart in Figure 3).
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4.3. Data Extractions and Synthesis
The papers were thoroughly reviewed by OC, LLG, VM and SD. Key information was extracted
from each study, and grouped into cohort characteristics (ethnicity/ country of the study, number
of patients), age of onset (distribution and mean and standard deviation (SD)), site of onset (spinal,
bulbar, respiratory, other/unknown), motor neurons being affected (UMN, LMN, UMN+LMN), disease
duration (mean and SD), percentage of patients with FTD, and percentage of patients with cognitive
impairment. All data are collated per gene in Table S2.
For the summary Table (Figure 4), the age of onset and disease duration are presented as the
weighted mean ± SD, and the site of onset, motor neuron impairments, and FTD comorbidity are
presented as weighted percentages, in all cases taking into account the number of patients studied as
described below:
Mean = mean of the parameter of interest given in the referenced study;
n = number of patients studied for the corresponding parameter in the given study;
Sx2 = SD2(n−1) + ((Sx)2/n)
Weighted mean =
∑
Sx∑
n
Weighted SD =
2
√
(
∑
(Sx2)−(∑ Sx)2)/∑n
(
∑
n)−1
4.4. Characteristics of Studies
A total of 1630 ALS patients were included in the systematic review. The total number of reported
patients for each gene is shown in Figure 4 column 4. As not all studies reported all clinical parameters,
the total number of patients studied for each parameter is reported in the first subcolumn for each
parameter. On average, 59% of the population was male, with considerable variation between genes
(See Table S2). Most of the studies were conducted in Europe, North America and Asia.
4.5. Overall Findings and Discussion
For most genetic forms of ALS reported in Table S2 and in Figure 4, the age of onset ranges
between 50 and 70 years old. Exceptions to this include cases of juvenile ALS, which are observed
with mutations in SPG11 [95,144], FUS [145,146] and ALS2 [53,55] (Table S2). Whilst FUS patients
are known to show considerable variation in phenotype, with some showing early onset and fast
progression, others show a later age of onset and a slower-progressing phenotype [147]. This variation
in the FUS phenotype has been hypothesised to arise due to the different effects exerted by missense
and truncating mutations [148]. Interestingly, the studies reviewed here suggest that FUS mutations
are indeed associated with a relatively early age of onset (41.8 ± 14.5 years) and a fast-progressing
phenotype, with average disease duration lasting 30.6 months (Figure 4). Another gene sometimes
associated with early-onset ALS is SETX. Patients with SETX mutations have been reported to display
a slow-progressing phenotype in which bulbar and respiratory muscles seem largely unaffected [149].
However, in one reported case, a patient did go on to experience bulbar symptoms 3 years after
onset [150]. Moreover, from the studies retrieved in this review, SETX patients do not show an early
age of onset nor a particularly slow phenotype. For instance, the average age of onset for SETX patients
was 59.5 ± 24.7 years with an average disease duration of 43.8 ± 37.5 months.
Many ALS-associated genes show variation in site of onset. Among the 22 genes included in
Figure 4, cases of spinal onset are predominant in 19. This is in line with previous findings that
suggest spinal onset accounts for approximately two-thirds of ALS cases [32]. For example, SOD1,
hnRNAP1, TUBA4A, and ALS2 show a high percentage of patients with spinal onset (>80%), while
spinal onset in VCP, NEK1, and TBK1 cases accounted for 50%, 50% and 55% of cases, respectively.
Some other ALS-associated gene mutations were associated with a lower proportion of spinal onset,
e.g., 33% of C9orf72 cases, and 40% of UBQLN2 cases. However, previous research suggests that
C9orf72 ALS demonstrates frequent occurrence of both spinal [151] and bulbar onset [152]. Moreover,
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it has been reported that site of onset in C9orf72 ALS can be used to predict disease duration. For
instance, the average age of onset in patients with spinal onset was 59.3 years, increasing to 62.3 years
in patients with bulbar onset, and male patients with spinal onset seem to display a faster-progressing
phenotype [153].
A striking 95% of SOD1 cases were classified as spinal onset. Indeed, animal studies have provided
support for the notion that SOD1 pathology begins at the periphery and proceeds in a retrograde
manner [154,155]. Recently, a homozygous mutation that eliminates the enzymatic activity of SOD1
was found to result in a severe LMN phenotype and mild cerebellar atrophy in a young child [156] and
the presence of a SOD1 p.D12Y variant was shown to result in a LMN-predominant phenotype [157].
Similarly, seven studies reported a non-negligible percentage of patients with pure LMN signs (Table
S2, Figure 4, 47.6% pure LMN vs. 45.2% UMN+LMN, [158–161]). Overall, these studies seem to
suggest that SOD1 mutations exert profound effects at the distal nerve. In addition, the observation
that both overexpression, and absence of SOD1 activity lead to pathology should be an important
consideration in the development of therapeutics that aim to alter SOD1 levels as a novel treatment in
ALS [162].
Figure 4 was sorted in descending order for the percentage of patients showing LMN signs.
Not all studies reported UMN and/or LMN signs, and thus the percentage given in this table only
represents a small proportion of the studies (see Table S2 for more details). However, it is interesting to
see that the majority of the gene mutations do indeed elicit a phenotype that is characterised by both
UMN+LMN signs, consistent with the classical clinical definition of ALS. FUS, C9orf72 and TARDBP
all demonstrated increased presence of both UMN and LMN signs with both neuronal populations
affected in 66.7%, 72.7% and 44.4%, respectively. Surprisingly, only 33% of FIG4, PFN1, MATR3 and
NEK1 cases showed both UMN and LMN signs, although it should be noted that 4 of the 14 studies
reviewed in relation to these genes did not provide details regarding the pattern of motor neuron
involvement. Some ALS-associated genes demonstrated >20% of patients with pure LMN signs (SOD1,
FUS, PFN1, ATXN2, TARDBP, TBK1, and hnRNPA1), while pure UMN signs had >20% preponderance
in several genes (ANG, TBK1, FIG4, MATR3, NEK1, hnRNPA1).
Finally, the current review also aimed to collect information regarding the prevalence of cognitive
impairments and FTD in ALS. FTD was most frequent in cases with mutations in either C9orf72,
SQSTM1, or TBK1 (36%, 67%, and 43%, respectively, Figure 4). Indeed, C9orf72 [163], SQSTM1 [164],
and TBK1 [165] have all previously been linked with FTD onset. However, in a large screen of 121
patients with FTD, genetic mutations were successfully identified only in C9orf72 and SQSTM1, whilst
no TBK1 variants were identified [166]. It is also worth noting that despite the frequent association
between TARDBP and FTD, only 12% of cases reviewed here were found to have concomitant FTD
symptoms. In relation to general cognitive functioning, reports of impairment were observed across 10
ALS-associated genes, although the number of patients studied for this parameter were often quite low
(Table S2), rendering it difficult to form conclusions.
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Figure 4. Table summarising the phenotypes observed in ALS patients with different mutations. A detailed version of this table is accessible as supplemental data
J. Pers. Med. 2020, 10, 58 13 of 28
(Table S2). PubMed was searched to identify published studies reporting genotype–phenotype data for 23 genes. Column 2 indicates the frequency of genes
observed in Caucasian populations described in previous reviews (Volk et al. [18] and Chia et al. [167]). The ethnicity/origin of cohorts reported across studies
is specified in Table S2 and summarised in column 3. For each parameter reported in this table, the number of patients is given in the first subcolumn for
each category. For age of onset, motor neuron impairments, disease duration, and FTD, the weighted mean ± SD, and weighted percentages are given, taking
into account the numbers of patients studied. Data for each gene were collected from the following reference studies, then summarized: hnRNPA1: [168];
SETX: [169–173]; SOD1: [24,92,160,161,171,172,174–188]; TBK1: [189–192]; FUS: [24,92,145,146,148,170–172,179,180,187,188,193–196]; OPTN: [171,180,187,197–203];
TUBA4A: [123,188,204,205]; TARDBP: [171,172,179,180,187,188,192,206–211]; ATXN2: [101,102,171,180,188,212–214]; C9orf72: [114,170,171,175,180,188,206,215–226];
MATR3: [227–231]; FIG4: [171,192,232]; ANG: [171,180,187,233–235]; NEK1: [131,236]; KIF5A: [137,141,143,237]; CCNF: [135]; PFN1: [238–241]; VAPB: [171,242,243];
UBQLN2: [244,245]; SQSTM1: [171,175,192,246]; VCP: [170,171,175,192,247]; SPG11: [179,248]; ALS2: [55,170]. Results from each separate study are shown in Table S2.
Gradient colour for age of onset from dark blue to dark red: dark blue, 16 years; dark red, 60 years. Gradient colour for site of onset and for motor neuron impairment
distributions: white, 0%; green, 100%.
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5. Conclusions
Over 150 years have passed since ALS was first reported by Charcot and still the aetiology of the disease
remains elusive. Although research is progressing and genetic studies continue to identify novel gene
associations [14,249–251], many questions remain surrounding the pathological mechanisms associated
with already established mutations, their role in the ALS phenotype, and the as yet undiscovered
mechanisms that underlie sporadic onset of disease. Here, we have performed a systematic review
in an attempt to highlight genotype–phenotype correlations for 23 of the more commonly reported
mutated genes in ALS. This has proven to be challenging as many genetic studies do not capture or
report a complete summary of clinical data. Whilst it is understandable that such data are difficult
to acquire, we hope to illustrate that there is a need for improved and more widely available clinical
and informatics resources that would enable genotype–phenotype associations to be easily visualised
in ALS.
Whilst we have illustrated the relationship between commonly reported mutated genes and various
clinical measures including age and site of onset, disease duration and motor neuron involvement, a
limitation of the current review is that we do not consider variation among phenotypes of patients
having different mutations of the same gene. For many genes involved in ALS, including FUS,
SOD1, and TARDBP, the phenotype may be different depending upon the specific genetic mutation
in question. In SOD1 patients, for instance, the A4V mutation results in a much more aggressive
phenotype (death occurring ~1.2 years after onset [252]) than the H46R mutation, for which patients
show a relatively mild phenotype (duration of ~17 years [253]). It could be of value in future work to
comprehensively review variations in genotype–phenotype correlations among the different mutations
reported by single-gene studies, which in turn could contribute towards a comprehensive database
of ALS genotype–phenotype correlation. Such a resource could ultimately improve our mechanistic
understanding of ALS by enabling a more robust assessment of how the ALS phenotype responds to
different variants across multiple genes.
Additional limitations include that many of the studies surveyed are relatively small, involving
low numbers of patients, and that, as well as only a subset of studies reporting clinical
breakdown of phenotype, ethnic breakdown is also not always reported and some ethnicities have
minimal representation.
Despite these limitations, the collected data reveal a landscape of highly variable phenotypic associations,
underlining the complexity of the disease, and the need for nuanced approaches to the development of
clinical assays and therapeutics.
Supplementary Materials: The following are available online at http://www.mdpi.com/2075-4426/10/3/58/s1,
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